FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to oncology and nutritional science, and concerns methods and nutritional formulations for increasing the effectiveness and reducing side effects of cancer treatment. To do this, a diet containing no more than 50% of the reference calorie intake with at least 50% of this value taken from fat is prescribed to the patient for the first 1-5 days. That is followed by prescribing a low-calorie diet of no more than 500 kcal a day to the patient for the next 2-7 days.
EFFECT: method provides cancer cell sensitisation to chemo- and/or radiation therapy increasing the anti-cancer effectiveness and reducing side effects.
28 cl, 57 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF SHORT-TERM FASTING MODE COMBINED WITH KINASE INHIBITORS FOR IMPROVEMENT OF TRADITIONAL CHEMO-MEDICINAL EFFECTIVENESS AND SUITABILITY AND REVERSAL OF SIDE EFFECTS OF KINASES IN NORMAL CELLS AND TISSUES | 2015 |
|
RU2697480C2 |
| FASTING MIMICKING DIET (FMD), AND GLUCOSE-LOWERING DRUGS, PROTECTING NORMAL CELLS AND CREATING CONDITIONS OF CANCER SENSITIZATION IN RESPONSE TO STANDARD CONDITIONS AND CONDITIONS WITH HIGH CONTENT OF GLUCOSE INDUCED BY RAPAMYCIN AND DEXAMETHASONE | 2016 |
|
RU2734774C2 |
| METHODS AND DIETS TO PROTECT AGAINST CHEMOTOXICITY AND AGE RELATED ILLNESSES | 2014 |
|
RU2674681C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| HUMANIZED ANTIBODIES TO THE THOMSEN-FRIEDENREICH ANTIGEN | 2015 |
|
RU2699717C2 |
| LECTIN-CONTAINING COMPOSITES AND THEIR USAGE | 1997 |
|
RU2202361C2 |
| METHODS AND COMPOSITIONS FOR DESTROYING AGING CELLS AND FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH AGING | 2015 |
|
RU2716256C2 |
| DNA COMPOSITION FOR INDUCING IMMUNE RESPONSE ON TUMOUR-ASSOCIATED MACROPHAGUES | 2007 |
|
RU2459631C2 |
